Eli Lilly (LLY): What an 81x EV/EBITDA Asks of the GLP-1 Franchise

The Most Expensive Fortress in Pharma Eli Lilly is arguably the defining pharmaceutical growth story of this decade. Its GLP-1 franchise — anchored by Mounjaro in diabetes and obesity — sits at the center of an addressable market our data pegs at $100B+, expanding at 15-20% annually. The market has noticed: at $1,004.92 per share, Lilly commands a $951.27B market capitalization, the largest in healthcare, on a P/E of 35.67. FairStock's quant engine scores the stock 61/100 with a STEADY verdict and classifies it as a Fast Grower — an unusual combination that captures the central tension here: exceptional business quality, priced for something close to perfection. Business Quality: Genuinely Exceptional The operating metrics read like a case study in pharmaceutical pricing power. Net margin reached 34.4% in the most recent quarterly data — extraordinary for a company still scaling manufacturing capacity. Return on equity stands at a staggering 107.46%, with return on capital employed of 19.4%, indicating that capital is being deployed into genuinely high-return opportunities rather than financial engineering alone (though leverage, discussed below, does amplify the ROE figure). The moat is structural. Patent protection, manufacturing scale in injectable biologics — a real barrier given global GLP-1 supply constraints — and entrenched positions in diabetes care via products like Mounjaro and Basaglar give Lilly durable pricing power in markets with secular, demographics-driven demand. A beta of 0.43 underscores the defensive character of essential medicines: demand for diabetes and obesity treatment does not follow the business cycle. The bull case is straightforward and powerful. Lilly owns the dominant GLP-1 franchise in one of the largest market opportunities in pharmaceutical history. If the company compounds revenue at 15%+ for a decade, as the obesity market matures from early adoption to standard-of-care, today's premium multiple gets absorbed by growth. T...